(DMP) Dermapharm Holding SE - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A2GS5D8
Branded Generics, OTC, Supplements, Dermatology, Parallel Import
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.31% |
| Yield on Cost 5y | 1.76% |
| Yield CAGR 5y | 0.56% |
| Payout Consistency | 87.1% |
| Payout Ratio | 78.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 29.1% |
| Value at Risk 5%th | 40.6% |
| Relative Tail Risk | -15.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -6.99 |
| CAGR/Max DD | 0.10 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.471 |
| Beta | 0.097 |
| Beta Downside | 0.257 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.16% |
| Mean DD | 18.39% |
| Median DD | 20.90% |
Description: DMP Dermapharm Holding SE November 11, 2025
Dermapharm Holding SE (XETRA:DMP) manufactures and sells off-patent branded pharmaceuticals across Germany, France, Spain, Austria, Switzerland and other markets, operating through three segments: Branded Pharmaceuticals, Other Healthcare Products, and a Parallel Import Business. Its portfolio spans branded generics, OTC items, vitamins, minerals, food supplements, and specialty products for dermatology, allergology, pain, cardiovascular health, gynecology, and urology, plus cosmetics, medical devices, and parallel-imported originator drugs under brands such as Dekristol, Keltican, and Herpotherm.
Key recent metrics (FY 2023) show revenue of roughly €300 million with an EBITDA margin near 12 %, reflecting the modest profitability typical of European generic players. The company’s growth is tied to demographic aging in Europe-driving demand for chronic-care generics-and to regulatory trends that increasingly favor cost-effective off-patent medicines. However, the parallel-import segment is exposed to tightening EU drug-pricing regulations, which could compress margins if policy tightens further.
For a deeper quantitative assessment, you may find the ValueRay platforms detailed valuation metrics useful.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (116.0m TTM) > 0 and > 6% of Revenue (6% = 69.6m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.24% (prev 21.41%; Δ 8.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 186.3m > Net Income 116.0m (YES >=105%, WARN >=100%) |
| Net Debt (864.3m) to EBITDA (311.7m) ratio: 2.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (53.8m) change vs 12m ago -0.11% (target <= -2.0% for YES) |
| Gross Margin 58.96% (prev 39.71%; Δ 19.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.72% (prev 54.59%; Δ 0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.92 (EBITDA TTM 311.7m / Interest Expense TTM 57.2m) >= 6 (WARN >= 3) |
Altman Z'' 2.93
| (A) 0.17 = (Total Current Assets 643.4m - Total Current Liabilities 292.6m) / Total Assets 2.12b |
| (B) 0.23 = Retained Earnings (Balance) 479.0m / Total Assets 2.12b |
| (C) 0.11 = EBIT TTM 224.2m / Avg Total Assets 2.12b |
| (D) 0.37 = Book Value of Equity 548.4m / Total Liabilities 1.47b |
| Total Rating: 2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.34
| 1. Piotroski 7.0pt |
| 2. FCF Yield 5.39% |
| 3. FCF Margin 12.43% |
| 4. Debt/Equity 1.56 |
| 5. Debt/Ebitda 2.77 |
| 6. ROIC - WACC (= 8.70)% |
| 7. RoE 18.56% |
| 8. Rev. Trend 55.14% |
| 9. EPS Trend -19.88% |
What is the price of DMP shares?
As of January 08, 2026, the stock is trading at EUR 38.90 with a total of 69,611 shares traded.
Over the past week, the price has changed by -1.14%, over one month by +2.37%, over three months by +16.82% and over the past year by +0.46%.
Over the past week, the price has changed by -1.14%, over one month by +2.37%, over three months by +16.82% and over the past year by +0.46%.
Is DMP a buy, sell or hold?
Dermapharm Holding SE has no consensus analysts rating.
What are the forecasts/targets for the DMP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47 | 20.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 42.1 | 8.3% |
DMP Fundamental Data Overview January 02, 2026
Market Cap USD = 2.12b (1.81b EUR * 1.1705 EUR.USD)
Market Cap EUR = 1.81b (1.81b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.9095
P/E Forward = 16.4474
P/S = 1.8044
P/B = 3.4831
Beta = 1.057
Revenue TTM = 1.16b EUR
EBIT TTM = 224.2m EUR
EBITDA TTM = 311.7m EUR
Long Term Debt = 933.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 77.5m EUR (from shortTermDebt, last quarter)
Debt = 1.01b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 864.3m EUR (from netDebt column, last quarter)
Enterprise Value = 2.68b EUR (1.81b + Debt 1.01b - CCE 146.6m)
Interest Coverage Ratio = 3.92 (Ebit TTM 224.2m / Interest Expense TTM 57.2m)
FCF Yield = 5.39% (FCF TTM 144.2m / Enterprise Value 2.68b)
FCF Margin = 12.43% (FCF TTM 144.2m / Revenue TTM 1.16b)
Net Margin = 10.00% (Net Income TTM 116.0m / Revenue TTM 1.16b)
Gross Margin = 58.96% ((Revenue TTM 1.16b - Cost of Revenue TTM 476.1m) / Revenue TTM)
Gross Margin QoQ = 36.44% (prev 67.66%)
Tobins Q-Ratio = 1.26 (Enterprise Value 2.68b / Total Assets 2.12b)
Interest Expense / Debt = 1.45% (Interest Expense 14.7m / Debt 1.01b)
Taxrate = 25.47% (14.1m / 55.2m)
NOPAT = 167.1m (EBIT 224.2m * (1 - 25.47%))
Current Ratio = 2.20 (Total Current Assets 643.4m / Total Current Liabilities 292.6m)
Debt / Equity = 1.56 (Debt 1.01b / totalStockholderEquity, last quarter 649.2m)
Debt / EBITDA = 2.77 (Net Debt 864.3m / EBITDA 311.7m)
Debt / FCF = 6.00 (Net Debt 864.3m / FCF TTM 144.2m)
Total Stockholder Equity = 625.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 116.0m / Total Assets 2.12b)
RoE = 18.56% (Net Income TTM 116.0m / Total Stockholder Equity 625.1m)
RoCE = 14.38% (EBIT 224.2m / Capital Employed (Equity 625.1m + L.T.Debt 933.4m))
RoIC = 13.18% (NOPAT 167.1m / Invested Capital 1.27b)
WACC = 4.48% (E(1.81b)/V(2.82b) * Re(6.37%) + D(1.01b)/V(2.82b) * Rd(1.45%) * (1-Tc(0.25)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 79.30% ; FCFE base≈137.7m ; Y1≈148.0m ; Y5≈181.3m
Fair Price DCF = 58.80 (DCF Value 3.17b / Shares Outstanding 53.8m; 5y FCF grow 8.36% → 3.0% )
EPS Correlation: -19.88 | EPS CAGR: -10.49% | SUE: 0.00 | # QB: 0
Revenue Correlation: 55.14 | Revenue CAGR: 2.11% | SUE: 0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=2.54 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+4.0%
Market Cap EUR = 1.81b (1.81b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.9095
P/E Forward = 16.4474
P/S = 1.8044
P/B = 3.4831
Beta = 1.057
Revenue TTM = 1.16b EUR
EBIT TTM = 224.2m EUR
EBITDA TTM = 311.7m EUR
Long Term Debt = 933.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 77.5m EUR (from shortTermDebt, last quarter)
Debt = 1.01b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 864.3m EUR (from netDebt column, last quarter)
Enterprise Value = 2.68b EUR (1.81b + Debt 1.01b - CCE 146.6m)
Interest Coverage Ratio = 3.92 (Ebit TTM 224.2m / Interest Expense TTM 57.2m)
FCF Yield = 5.39% (FCF TTM 144.2m / Enterprise Value 2.68b)
FCF Margin = 12.43% (FCF TTM 144.2m / Revenue TTM 1.16b)
Net Margin = 10.00% (Net Income TTM 116.0m / Revenue TTM 1.16b)
Gross Margin = 58.96% ((Revenue TTM 1.16b - Cost of Revenue TTM 476.1m) / Revenue TTM)
Gross Margin QoQ = 36.44% (prev 67.66%)
Tobins Q-Ratio = 1.26 (Enterprise Value 2.68b / Total Assets 2.12b)
Interest Expense / Debt = 1.45% (Interest Expense 14.7m / Debt 1.01b)
Taxrate = 25.47% (14.1m / 55.2m)
NOPAT = 167.1m (EBIT 224.2m * (1 - 25.47%))
Current Ratio = 2.20 (Total Current Assets 643.4m / Total Current Liabilities 292.6m)
Debt / Equity = 1.56 (Debt 1.01b / totalStockholderEquity, last quarter 649.2m)
Debt / EBITDA = 2.77 (Net Debt 864.3m / EBITDA 311.7m)
Debt / FCF = 6.00 (Net Debt 864.3m / FCF TTM 144.2m)
Total Stockholder Equity = 625.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 116.0m / Total Assets 2.12b)
RoE = 18.56% (Net Income TTM 116.0m / Total Stockholder Equity 625.1m)
RoCE = 14.38% (EBIT 224.2m / Capital Employed (Equity 625.1m + L.T.Debt 933.4m))
RoIC = 13.18% (NOPAT 167.1m / Invested Capital 1.27b)
WACC = 4.48% (E(1.81b)/V(2.82b) * Re(6.37%) + D(1.01b)/V(2.82b) * Rd(1.45%) * (1-Tc(0.25)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 79.30% ; FCFE base≈137.7m ; Y1≈148.0m ; Y5≈181.3m
Fair Price DCF = 58.80 (DCF Value 3.17b / Shares Outstanding 53.8m; 5y FCF grow 8.36% → 3.0% )
EPS Correlation: -19.88 | EPS CAGR: -10.49% | SUE: 0.00 | # QB: 0
Revenue Correlation: 55.14 | Revenue CAGR: 2.11% | SUE: 0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=2.54 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+4.0%